Tutti gli studi
AutorizzatoConferma terapeutica (Fase III)Interventistico

An Open-label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of 12-month Treatment with Migalastat in Pediatric Subjects (aged 2 to < 12 years) with Fabry Disease and Amenable GLA Variants

This research study is testing a medicine called migalastat for children aged 2 to under 12 years old who have Fabry disease. Fabry disease is a rare genetic condition that can affect many parts of the body. The study aims to understand how safe the medicine is for children and how well it works over a 12-month period. Researchers will look at how the body handles the medicine, whether it helps improve symptoms, and if there are any side effects. The information gathered will help doctors decide if migalastat is a good treatment option for younger children with Fabry disease, particularly those with specific genetic changes that the medicine is designed to help.

A colpo d'occhio

Stato
Autorizzato
Fase
Conferma terapeutica (Fase III)
Sponsor
Amicus Therapeutics Inc.
Obiettivo di iscrizione
3
Inizio
17 Dic 2025

Di cosa tratta questo studio?

This study is about a medicine called migalastat, and it's for children aged 2 to under 12 years old who have Fabry disease. Fabry disease is a rare condition that means the body can't properly break down a certain type of fat, which then builds up in cells and can cause problems in organs like the kidneys, heart, and skin. Migalastat is already approved for adults with Fabry disease who have specific genetic changes (called 'amenable GLA variants'), and this study wants to see if it's safe and effective for younger children too.

The main goals are to check how safe the medicine is for children and how well their bodies use it – for example, how much of it gets into their blood and how long it stays there. The study will also look to see if the medicine helps improve overall health and if there are any side effects over 12 months. This type of study, called a Phase 3 study, is usually done to confirm that a treatment is helpful and safe before it can be more widely used.

Finding safe and effective treatments for children with Fabry disease is very important. If successful, this study could lead to migalastat becoming an approved treatment option for younger children, giving them access to medication that might help manage their condition earlier in life.

Punti chiave

  • This study is for children aged 2 to under 12 with a specific type of Fabry disease.
  • It aims to check the safety and effectiveness of migalastat over 12 months.
  • Children will have regular medical check-ups and tests.
  • La partecipazione è volontaria e puoi ritirarti in qualsiasi momento.
  • This research could help doctors understand if migalastat is a good treatment for younger children.

Chi può essere idoneo?

To join this study, children need to be between 2 and under 12 years old and have Fabry disease. Importantly, they must have a specific type of genetic change (doctors call them 'amenable GLA variants') that the medicine, migalastat, is designed to work with.

Children of any gender can take part. The study team will review each child's health and medical history very carefully to make sure the study is a good fit for them and that it's safe for them to participate. They'll also check if there are any other reasons why a child might not be able to join, such as other serious health conditions or taking certain medications.

It's worth remembering that these are just the basic requirements. A doctor involved in the study will be able to tell you all the detailed specific things that would make a child eligible or not eligible.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. Is your child aged between 2 and under 12 years old?
  2. Does your child have a diagnosis of Fabry disease?
  3. Has your child's doctor confirmed they have a specific genetic change that migalastat can treat?
  4. Is your child able to come for regular clinic visits and tests?
  5. Does your child meet other health requirements as determined by the study doctors?
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

If your child takes part in this study, they will receive the study medicine, Migalastat Hydrochloride, as a dispersible tablet for 12 months. This means it's a tablet that can be dissolved in liquid. Throughout the study, your child will have regular visits to the clinic. At these visits, doctors and nurses will closely monitor their health. This will include checking their blood and urine, taking vital signs like blood pressure and heart rate, doing physical examinations, and measuring their weight and height. They’ll also have tests like heart scans (echocardiograms) and electrocardiograms (ECGs) to check their heart health. For older girls (8 years and up) and boys (9 years and up), their growth and development will also be checked. After the 12 months of treatment, there will be follow-up appointments to see how your child is doing. The total duration of active participation, including follow-up, will be longer than just the 12 months of taking the medicine.

Rischi e benefici potenziali

Taking part in any medical study has potential benefits and risks. A potential benefit could be that your child receives a treatment that might improve their Fabry disease, and you'll receive close medical monitoring. However, there's no guarantee the medicine will work for your child, and they might experience side effects. These could include common side effects of migalastat or unexpected reactions. All medical procedures and tests also carry some minor risks. You will be given a document that explains all known potential risks and benefits in detail. Remember, you have the right to withdraw your child from the study at any time, for any reason, without it affecting their future medical care.

Luoghi (3)

Alcune posizioni dei siti sono approssimative. Stiamo migliorando questo — si prega di verificare con il team di prova prima di viaggiare.
  • —
    Non verificato
    Spagna
  • —
    Non verificato
    Germania
  • —
    Non verificato
    Belgio

Domande comuni

What is Fabry disease?

Fabry disease is a rare genetic condition where the body can't properly break down a certain type of fat. This fat then builds up in different parts of the body, potentially causing problems in organs like the kidneys, heart, and skin.

What is Migalastat?

Migalastat is a medicine already approved for adults with Fabry disease who have specific genetic changes. It's now being studied to see if it's safe and helpful for children.

How long will my child take the medicine?

Children in this study will take the medicine, Migalastat, for 12 months.

Will my child need to stay in the hospital?

No, this study doesn't typically require hospital stays. Your child will have regular clinic visits for check-ups and tests.

Can my child stop the study if they want to?

Yes, you have the right to withdraw your child from the study at any time, for any reason. Your child's future medical care will not be affected.

Come saperne di più

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.